| abstract |
Refers to a pharmaceutical composition comprising at least 150 mg and up to 700 mg of Ceritinib and more than 40% and up to 70% by weight of Ceritinib based on the total weight of the pharmaceutical composition, wherein the composition comprises granules consisting of substantially from Ceritinib and a binder where the granules are obtainable by wet granulation; the binder is starch, hypromellose, povidone, among others, said composition also comprises other excipients. It also refers to a pharmaceutical form and a procurement process. Said composition inhibits the anaplastic lymphoma kinase (ALK) enzyme, being useful in the treatment of proliferative disease such as non-small cell lung cancer. |